Entrepreneurship 101: From Research to Business Development & Licensing -- When science and business make a perfect blend

Entrepreneurship 101 - Science and Business do Mix Mathieu Boudreau MaRS Lecture Series March 13, 2007 From Research to Business Development & Licensing – When Science and Business Make a Perfect Blend

Preface ,[object Object],[object Object],[object Object],[object Object]

Outline ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Background on Doctoral Studies ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

How it All Started ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],How it All Started

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],How it All Started

Facing Choices ,[object Object]

The Rise.... ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

.... And Fall of a Start-up ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

What Would I do Differently? ,[object Object],[object Object],[object Object],[object Object],[object Object]

What Did I Learn From This? ,[object Object],[object Object],[object Object],[object Object],[object Object]

What Did I Learn From This? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Aegera Programs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Aegera’s Focus Apoptosis Control Drugs ,[object Object],Neuropathy & Pain ,[object Object],[object Object],[object Object],[object Object],Prevent Facilitate A P O P T O S I S

Pipeline Status/Projections ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],TARGETED APOPTOSIS CONTROL AEGERA R&D STRATEGY THERAPEUTIC AREAS TARGETS/ MECHANISM PRODUCT/ NME ,[object Object],XIAP Knock Down 2 nd Generation Antisense (AEG35156) ,[object Object],[object Object],[object Object],Pan IAP Suppression Small Molecule Inhibitors ,[object Object],[object Object],[object Object],JNK Pathway/ HSP Small Molecule Modulators ,[object Object],[object Object],[object Object],Apoptosis Regulation Small Molecules Internal Internal Internal In-Licensing/M&A

Proprietary Targets: IAP Protein Family (IAP = “Inhibitor of Apoptosis Protein”) XIAP Expression in Pancreatic Cancer ,[object Object],[object Object],[object Object],[object Object],“ The IAPs…are the most powerful intrinsic inhibitors of cell death. ….IAP antagonists are promising candidates for anticancer therapies…” U. Fischer, K. Schulze-Osthoff “ Apoptosis-based therapies and drug targets”, Cell Death and Differentiation , 2005

XIAP: A Validated Cancer Target ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Aegera Compounds Demonstrate Neuroprotective Activity and Pain Relief Pain Relief & RNAi suppression of HSP70 blocks cmpd-induced JNK inhibition Cmpds fail to induce HSP70 in HSF1 knock out cells JNK CASPASE 3 CASPASE 9 MITO Cyto C CASPASE 7 Bad Bim Cell Survival HSP70 HSP5 others ... HSF1 HSF1 HSF1 HSP70 HSF1 Induces HSP70 HSF1 HSF1 HSP90 Compounds bind to HSP90 and release HSF1 HSP70 potently Inhibits JNK

Potential Therapeutic Areas Based on MOA Ischemia & Stroke (excitotoxicity) CDT CNS Neuro Disorders 63-7 [2005] Alzheimer’s Disease Am J Alz Other Demen 79-88 [2002] Parkinson’s Disease IUBMB Life 267-71 [2003] Huntington’s Disease Neuroscience 859-70 [2004] Diabetic Neuropathy FASEB 15: 2508 [2001] JBC 278: 23151 [2003] Diabetologia 49(3): 580 [2006] Mol Pharm. 70:1246 [2006] Taxol Neurotoxicity J. Neurosci. 21: 4657 [2001] JBC 278: 567 [2003] Neuropathic Pain Pain 99: 175 [2002] Biochem. Biophys. Res.Comm. 335: 132 [2005] J. Neurosci. 26(13): 3551 [2006] Axotomy-induced Neuronal Death JBC 280: 1132 [2005] HIV-induced PN Exp. Neurol. 188: 246 [2004] Stress-induced Death of SCGs and DRGs JBC 276: 4531 [2001] CNS PNS

Experienced Management Team Shire, Biochem Pharma, NCI (National Cancer Institute) 26 VP Clinical Jacques Jolivet, M.D. NRC, U of Ottawa, Salk Institute 28 VP Drug Discovery Jon Durkin, Ph.D. Telecom, TD Securities 18 Chief Operating Officer & Chief Financial Officer Donald Olds, M.Sc., MBA BioChem Pharma, Merck 29 Chief Scientific Officer John Gillard, Ph.D. RCT, AEA Investors, Bayer, Pfizer 24 President & CEO Michael Berendt, Ph.D. Prior Experience Years of Experience Title Name

Aegera Development Pipeline CANDIDATE SELECTION PHASE 1 PHASE 2 PHASE 3 AEG35156 Small Molecule IAP Antagonists Mono Small Molecule Neuropathy/Pain Combination

Aegera Development Pipeline - 2008 CANDIDATE SELECTION PHASE 1 PHASE 2 PHASE 3 AEG35156 Small Molecule IAP Antagonists Mono Small Molecule Neuropathy/Pain Combination Small Molecule Licensed

Aegera In-Licensing Criteria ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Contact: Aegera Therapeutics Inc. 810 Chemin du Golf Montreal, Quebec H3E 1A8 T: 514-288-5532; F: 514-288-9280 www.aegera.com

What’s My Job Like? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

What’s Next ,[object Object],[object Object],[object Object],[object Object],[object Object]

Entrepreneurship 101: From Research to Business Development & Licensing -- When science and business make a perfect blend

Recommandé

Recommandé

Contenu connexe

Plus de MaRS Discovery District

Plus de MaRS Discovery District (20)

Dernier

Dernier (20)

Entrepreneurship 101: From Research to Business Development & Licensing -- When science and business make a perfect blend